Emerging hematological targets and therapy for cardiovascular disease: From bench to bedside
Authors Villegas A, Gonzalez FA, Llorente L, Redondo S
Published 12 September 2008 Volume 2008:2(3) Pages 397—407
Ana Villegas, Fernando A Gonzalez, Leopoldo Llorente, Santiago Redondo
Service of Hematology and Hemotherapy, Hospital Clinico Universitario San Carlos, Madrid, Spain
Abstract: Atherosclerotic cardiovascular disease is the leading cause of death and a major part of its pathophysiology remains obscure. Some hematological targets have been related to the development and clinical outcome of this disease, especially soluble cytokines, leukocytes, red blood cells, hemostatic factors and platelets, and bone-marrow vascular progenitors. These emerging factors may be modulated by current antiatherosclerotic pharmacotherapy, target-designed novel drugs or progenitor cell therapy. The aim of current review article is to comprehensively review the role of these antiatherosclerotic targets and therapy.
Keywords: atherosclerosis, blood, progenitor cells, cytokines, therapy
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]